Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer

1 Aug 2025

Abstract excerpt

Colorectal cancer (CRC) ranks among the most commonly diagnosed cancers globally and is characterized by high mortality rates and significant intertumoral heterogeneity driven by somatic mutations and an immunosuppressive tumor microenvironment (TME). Despite the success of immune checkpoint blockers (ICBs) in various malignancies, the immunosuppressive TME limits their therapeutic efficacy in the majority of CRC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to interferon and immune responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40750787
DOI: 10.1038/s41419-025-07912-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancerPMID 40750787Read ↗

Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsSemantic proximity Read ↗

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune responseSemantic proximity Read ↗

ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal CancerSemantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective studySemantic proximity Read ↗

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.Semantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancerSemantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS- STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

ATM inhibition enhance antitumor immunity of CRC by activating cGAS/STING and NFκB/IRF1/NLRC5 pathwaySemantic proximity Read ↗

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.